A Study of the Safety and Efficacy of EBV Specific T-cell Lines (EBV-TCL-01)
Epstein-Barr Virus Infections, Post-Transplant Lymphoproliferative Disorder, Lymphoma
About this trial
This is an interventional treatment trial for Epstein-Barr Virus Infections focused on measuring Allogeneic Transplantation, T cell, Epstein-Barr Virus
Eligibility Criteria
Inclusion Criteria:
- Capacity to provide informed consent
- Age ≥ 18 years old
- Confirmed treatment-refractory EBV reactivation or EBV-related lymphoma
- ECOG of 2 or less
Exclusion Criteria:
- Medical condition requiring a corticosteroid dose greater than Prednisone 0.5mg/kg/day (or equivalent) at the time of the infusion.
- Patient has received T-cell depleting antibodies or stem cell transplantation in the 28 days prior to proposed date of anti-EBV T-cell line infusion
- Patient has received a solid organ transplant in the 3 months prior to proposed date of anti-EBV T-cell line infusion.
- Pregnant or nursing females
- Life expectancy of less than 3 months due to a condition unrelated to the EBV- related disease.
- Active uncontrolled GVHD
- Active uncontrolled SOT rejection episode
DONOR ELIGIBILITY: An allogeneic donor must be a first-degree relative with at least 3/6 HLA compatibility, have consented to donate peripheral blood mononuclear cells, and fulfill the same criteria for stem cell donation according to the hospital's standard operating procedure.
Sites / Locations
- Hôpital Maisonneuve-RosemontRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Autologous or allogenic (stem cell donor) T cells
Allogeneic "third party" T cells
Subjects receive an autologous anti-EBV T-cell line or a T-cell line derived from the patient's allogeneic (stem cell transplant) donor.
Subjects receive a T-cell line from a matched or partially matched related donor.